麻豆视频

Market Trends and Insights

Expanding Adoption of Point-of-Care (POC) Diagnostics

Regulators expanded CLIA-waived categories in 2024 and 2025, allowing pharmacies and employer clinics to perform rapid strep, influenza, and lipid panels without requiring laboratory staff. Retail chains such as CVS Health and Walgreens now capture routine tests that once flowed to reference labs, forcing central facilities to specialize in esoteric sequencing and autoimmune panels.^{[1]鈥淐VS Health Expands Access to Care with New MinuteClinic Services,鈥� CVS Health, cvshealth.com} FDA clearance of Dexcom鈥檚 over-the-counter continuous glucose monitor in 2024 demonstrated that consumer electronics firms can bypass legacy infrastructure entirely. Handheld immunoassay readers and smartphone-linked lateral-flow devices meet hospital-grade precision, narrowing the performance gap that protected central labs. This decentralization boosts test access but squeezes reagent volumes in high-margin hospital settings.

High Prevalence of Chronic Diseases

Diabetes, cardiovascular disease, and chronic kidney disease drove 1.3 billion diagnostic procedures in 2025, straining global laboratory capacity.^{[2]鈥淒iabetes,鈥� World Health Organization, who.int} Diabetes prevalence climbed to 537 million adults in 2024, with the fastest growth in South Asia and the Middle East. Each chronic-care patient requires serial lipid, troponin, and kidney-function assays, raising consumable demand even as reimbursement remains flat. Wearable biosensors now continuously stream glucose and lactate data, shifting some monitoring from venipuncture to cloud analytics. Vendors, therefore, bundle laboratory reporting with longitudinal analytics subscriptions to preserve revenue even as traditional consumable sales plateau.

Aging Population Boosting Chronic Disease Testing Volumes

Citizens aged 65 plus generate a disproportionate share of chemistry panels. Japan鈥檚 over-75 cohort alone accounted for 47% of all clinical-chemistry tests in 2024.^{[3]鈥淢inistry of Health, Labour and Welfare, Japan,鈥� mhlw.go.jp} Reimbursement cuts compelled laboratories to automate, integrating cartridge-based multiplex assays that combine hemoglobin A1c, creatinine, and lipid markers in a single run, thereby reducing labor time per specimen. China鈥檚 2025 rural screening program for residents over 60 secured fixed-price contracts favoring high-volume reagent producers. Rising cancer incidence within aging populations likewise increases demand for tumor markers and liquid-biopsy monitoring, embedding advanced diagnostics deep into chronic-care pathways.

Growing Infectious-Disease Burden Fueling Rapid Diagnostics

Following the pandemic, hospitals adopted multiplex PCR panels that detect up to 30 pathogens in a single cartridge, maintaining high utilization even as COVID-19 testing subsided. WHO reported 10.8 million new tuberculosis cases in 2024, with 410,000 drug-resistant infections requiring two-hour molecular resistance profiling. Donor-funded programs distributed 120 million malaria rapid tests in 2024, reinforcing demand for low-infrastructure assays across Sub-Saharan Africa. Primary-care sites value a 15-minute turnaround, which improves antimicrobial stewardship and reduces hospital admissions, thereby sustaining growth in molecular diagnostics.

Stringent Multi-Region Regulatory Approval Timelines

The European Union鈥檚 IVD Regulation, fully enforced in May 2024, transitioned thousands of low-risk assays from self-certification to notified-body review, resulting in a median approval time of 22 months. Japan and China impose parallel data requirements, adding 18 to 24 months before multinational launches reach the Asia region. Small innovators lack the regulatory manpower to run simultaneous trials, so they prioritize the United States first, ceding early share abroad. Staggered launches delay global scale and allow fast-follower rivals to secure reimbursement ahead of pioneers, marginally shaving the in vitro diagnostic market CAGR.

Reimbursement Uncertainty Across Emerging Test Classes

CMS issued non-coverage decisions for several multi-cancer early-detection tests in 2024 due to the limited availability of mortality data. Private insurers echoed the stance, forcing laboratories to self-pay or negotiate risk-sharing contracts. FoundationOne CDx receives a Medicare reimbursement of USD 5,800, whereas comparable assays lacking FDA approval often face claim denials. Laboratories hesitate to deploy costly oncology panels until reimbursement is stabilized, slowing the adoption curve even after regulatory clearance.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

In Vitro Diagnostic Market Segment Analysis

Reagents and kits accounted for 54.28% of 2025 revenue, underscoring the consumable-based economics that sustain most laboratories. Hospitals favor reagent-rental agreements that waive analyzer acquisition costs in exchange for multi-year consumable purchases, a model that smooths vendor revenue. Software and services are forecast to post a 10.29% CAGR through 2031, powered by AI decision-support, cloud-hosted middleware, and remote instrument diagnostics. Instruments remain vital as lock-in platforms; Siemens Healthineers鈥� Atellica Solution processes 440 tests per hour and auto-verifies 85% of results, saving labor minutes per report. The in vitro diagnostic market size for software is currently small, but its double-digit trajectory signals a shift by laboratories toward analytics and compliance outsourcing. 

Software now decouples from hardware under the FDA鈥檚 Software-as-a-Medical-Device framework, enabling independent algorithm upgrades. Vendors differentiate by pairing cloud dashboards with quality-control materials, creating sticky ecosystems. As capital budgets tighten, revenue from reagent rental and subscription-based software will rise faster than hardware placements, reshaping vendor profit pools within the in vitro diagnostic market.

Immunoassay retained a 26.63% revenue share in 2025, driven by thyroid, cardiac, and tumor markers. Yet, molecular diagnostics are projected to expand at an 8.21% CAGR, driven by liquid biopsy approvals, CRISPR assays, and syndromic infectious disease panels. Clinical chemistry automation has commoditized metabolic panels, so vendors now differentiate themselves through faster throughput and middleware integration rather than reagent chemistry. Hematology platforms incorporate AI-based cell classification, while microbiology shifts from culture to MALDI-TOF for rapid identification in 15 minutes. 

Technology convergence is blurring legacy silos; next-generation platforms combine immunoassay, molecular techniques, and mass spectrometry on a single track. Laboratories welcome consolidated workflows that reduce sample handling, minimize error risk, and contain labor costs. As these hybrid systems scale, the in vitro diagnostic market will shift toward multi-modal analyzers that integrate AI-driven sample triage, increasing switching costs and solidifying vendor relationships.

Infectious diseases accounted for 41.76% of 2025 revenue, buoyed by multiplex respiratory panels that remained in use after the pandemic peaks. Growth, however, is moderating as COVID-19 volumes return to normal. Oncology diagnostics, in contrast, are projected to increase by 9.94% per year to 2031, driven by companion diagnostics and minimal residual disease liquid biopsies, such as Guardant360. Diabetes testing remains a high-volume market but faces price pressure as continuous glucose monitors become available over the counter. 

Cardiology markers are migrating to emergency department POC settings, while autoimmune and nephrology panels are gaining market share through multiplex formats that enhance diagnostic efficiency. Oncology鈥檚 higher reimbursement and clinical urgency drive capital investment in sequencing, flow cytometry, and mass spectrometry, positioning cancer testing as the fastest-growing slice of the in vitro diagnostic market.

Hospitals and academic centers accounted for 48.28% of 2025 revenue, primarily driven by stat and high-complexity assays that require advanced infrastructure. Point-of-care sites, pharmacies, urgent care clinics, and employer health centers are forecasted to grow at a 7.94% CAGR, propelled by waived cartridges that deliver immediate results. Reference laboratories scale esoteric menus but endure payer pressure on routine panels. Home and over-the-counter channels remain small but exhibit steep growth as the FDA clears consumer diagnostics, such as continuous glucose monitors. 

End-user fragmentation compels vendors to tailor offerings: compact analyzers for POC clinics, automation lines for hospitals, and cloud portals for at-home results. This segmentation increases touchpoints for the in vitro diagnostic market, expanding the total addressable volume but requiring versatile portfolios and adaptive go-to-market models.

Geography Analysis

North America In Vitro Diagnostic Market

North America accounted for 37.16% of the 2025 revenue, supported by early adoption of molecular diagnostics and robust reimbursement. CMS value-based-care models now tie laboratory utilization to bundled payments, pressuring providers to limit low-value testing. FDA cybersecurity mandates increase compliance costs but improve data integrity. Canada and Mexico consolidate testing into regional hubs to capture scale economies. 

APAC In Vitro Diagnostic Market

The Asia-Pacific region is forecast to post a 7.19% CAGR from 2026 to 2031, the fastest regional pace. China鈥檚 volume-based procurement slashed reagent prices by up to 60%, yet soaring volumes protect vendor revenue. India鈥檚 National Health Mission funded 5,000 district labs in 2024-25, increasing per-capita test penetration from 0.08 to 0.15 tests per capita annually. Aging Japan and South Korea are automating aggressively to offset labor shortages, resulting in increased capital expenditure on total laboratory automation. 

EMEA and South America In Vitro Diagnostic Market

Europe enforces the IVD Regulation, extending approval timelines and favoring multinationals with seasoned regulatory teams. GCC states channel oil revenue into laboratory infrastructure under Vision 2030. Sub-Saharan Africa remains under-penetrated but benefits from donor-funded HIV, tuberculosis, and malaria programs. South American laboratories struggle with currency fluctuations and import tariffs, sourcing reagents locally whenever possible to manage costs.

Regulatory Landscape

Regulatory requirements continue to diverge by region, with several 2024-2026 milestones shaping global launch sequencing and compliance costs. In the European Union, Regulation (EU) 2017/746 (IVDR) moved fully into force in May 2024, shifting many assays from self-certification to Notified Body review and extending time-to-market. The European Commission continued publishing updated information on Notified Body designation and application status in 2026 to support transition capacity planning.

In the United States, the FDA finalized a Laboratory Developed Test (LDT) framework in 2024, and Stage 1 of the phaseout policy began in May 2026. This brings medical device reporting, correction and removal reporting, and defined quality system complaint-file obligations into scope for affected laboratories. Quality management and reliance initiatives are also increasing the weight of harmonized standards in IVD quality systems and post-market processes. The FDA is implementing its Quality Management System Regulation (QMSR), aligning device quality system requirements more closely with ISO 13485 and updating inspection approaches during the transition period. At the multilateral level, WHO and the International Medical Device Regulators Forum (IMDRF) continue to promote reliance-based regulatory pathways via the WHO Global Model Regulatory Framework and the IMDRF Reliance Playbook (N89), providing a reference point for regulators and manufacturers seeking to reduce duplicative evidence generation across jurisdictions.

Market Opportunities and Future Outlook

Regulatory transition work in Europe and the scaling of compliance infrastructure are creating whitespace for consultative services, regulatory tooling, and portfolio rationalization that favors manufacturers able to sustain multi-year certification programs under IVDR. Concrete 2026 deadlines, such as the May 26, 2026 application lodging date for legacy Class C IVDs with an EU Notified Body and the May 28, 2026 EUDAMED use requirement for new IVDs, are pushing companies to refresh technical documentation, strengthen post-market surveillance processes, and prioritize assays with clearer reimbursement and clinical demand. In parallel, the European Commission published a simplification package in December 2025 (COM(2025) 1023 final) proposing amendments to MDR/IVDR to reduce administrative burden and address capacity constraints, giving manufacturers an active policy track to monitor when planning EU portfolios and submission timing.

On the supply and technology side, capacity localization and higher-throughput molecular manufacturing investments point to where vendors are committing capital to support faster menu expansion and resilience. In May 2026, bioMerie虂ux announced a EUR 250 million investment in a new PCR test manufacturing facility in La Balme-les-Grottes, France (planned to be operational in 2030), reinforcing regional manufacturing for molecular diagnostics. In May 2026, Natera disclosed an expansion in Austin, Texas, adding dedicated sequencing capacity, while India continued to attract manufacturing buildout, including a June 2026 opening of a new IVD-focused medical device facility by Lord's Mark Industries. Together, these steps support opportunities around scalable PCR and sequencing workflows, automation-ready consumables, and software and services that help laboratories integrate decentralized testing, cybersecurity controls, and cross-site quality management.